Vaxart, Inc. (VXRT)

3.7200 +0.2000 (+5.68%) As of 04:00PM EDT. Market open.

Vaxart, Inc.

170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States
650 550 3500
https://vaxart.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 110

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Cezar Andrei Floroiu M.B.A.	CEO, Pres, Principal Financial Officer & Director	538.15k	N/A	1973
Ms. Margaret A. Echerd	Sr. VP & Principal Accounting Officer	523.07k	N/A	1959
Dr. Sean N. Tucker	Sr. VP & Chief Scientific Officer	530.72k	N/A	1968
Mr. Edward B. Berg	Sr. VP & Gen. Counsel	N/A	N/A	N/A
Ms. Shaily Jaini Garg	Sr. VP of Clinical Devel. & Project Management	N/A	N/A	N/A
Mr. Brant Biehn	Sr. VP of Bus. Operations	N/A	N/A	N/A
Dr. Richard M. Schwartz	Sr. VP of Technical Operations	N/A	N/A	N/A
Dr. Rajesh Kapoor Ph.D.	Sr. VP of Quality	N/A	N/A	N/A
Dr. James F. Cummings M.D.	Chief Medical Officer	N/A	N/A	N/A
Mr. John M. Harland M.B.A., CPA	Consultant	N/A	N/A	1952

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Corporate governance

Vaxart, Inc.’s ISS governance QualityScore as of 1 May 2022 is 7. The pillar scores are Audit: 10; Board: 5; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.